je.st
news
Tag: phase
Richardson RFPD Introduces New Phase and Amplitude Controller For Doherty Amplifiers From Peregrine
2016-03-04 06:12:39| rfglobalnet Home Page
Richardson RFPD, Inc. announced recently the availability and full design support capabilities for a new monolithic phase and amplitude controller (MPAC) from Peregrine Semiconductor Corporation.
Tags: from
phase
controller
introduces
Ted Baker rolls out second phase of PLM project
2016-03-01 13:39:00| Daily apparel & textile news and comment - from just-style.com
UK fashion brand Ted Baker has successfully rolled out the second phase of its product lifecycle management (PLM) project, extending it to its women's wear team.
Compact OCXO offers ultra-low phase noise performance.
2016-02-24 14:31:04| Industrial Newsroom - All News for Today
Available from 10–120 MHz with +10 dBm sinewave output, YH1485 OCXO (oven controlled crystal oscillator) features low phase noise down to -180 dBc/Hz. Acceleration sensitivity is available down to <3 x 10-10/g for better performance during shock and vibration, which respectively carry ratings per MIL-STD-202 (Meth 213, Cond C) and vibration per MIL-STD-202 (Meth 204, Cond A). Supplied in 1 in.², low-profile package, OCXO uses +15 or +12 Vdc supply and features EFC.
Tags: offers
performance
phase
compact
JCP&L Begins Construction on Second Phase of Transmission Project
2016-02-22 19:19:00| Transmission & Distribution World
Jersey Central Power & Light has started construction on the final segment of a new 11.5-mile transmission line project. read more
Tags: project
construction
phase
transmission
Mercks Investigational Once-Daily Formulation of ISENTRESS (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study
2016-02-22 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Results to be Presented at Future Medical Meeting, and Regulatory Submissions Planned for 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced top-line results from the companys Phase 3 pivotal trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily formulation of ISENTRESS (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg once-daily), for previously untreated HIV-1 infected adults. Language: English Contact: For MerckMedia:Pamela Eisele, 267-305-3558orCarmen de Gourville, 267-305-4195orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
primary
phase
secondary
Sites : [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] next »